54 results
PRE 14A
GLYC
GlycoMimetics Inc
22 Mar 24
Preliminary proxy
5:00pm
for that company’s worldwide commercialization and portfolio strategy across oncology, neurosciences and rare diseases. From February 2017 to February … officer, as well as her in-depth knowledge of operations and commercial strategy.
Mark Goldberg, M.D., age 69
Dr. Goldberg has served as a member
8-K
EX-99.1
GLYC
GlycoMimetics Inc
3 Nov 23
GlycoMimetics Reports Highlights and Financial Results for Third Quarter 2023
8:35am
ability and ambition to deliver our development strategy and move closer to becoming a commercial stage company.”
Operational Highlights
Uproleselan
8-K
EX-99.1
GLYC
GlycoMimetics Inc
2 Aug 23
GlycoMimetics Reports Highlights and Financial Results for Second Quarter 2023
8:35am
of GlycoMimetics. “We continue to execute our broad development strategy for uproleselan while we explore potential benefit in AML patients of all
8-K
EX-99.1
4343k9
4 Oct 22
Regulation FD Disclosure
5:03pm
424B5
1ox2h83i
28 Apr 22
Prospectus supplement for primary offering
5:01pm
8-K
EX-99.1
h9cvqw5a
3 Mar 22
GlycoMimetics Reports Highlights and Financial Results
8:45am
8-K
q9tfh
5 Aug 21
Glycomimetics Reports Highlights and Financial Results
8:01am
8-K
EX-99.2
sg6dp o5c36m6whgs5u8
5 Aug 21
Glycomimetics Reports Highlights and Financial Results
8:01am